Tag Archives: KIT

Science & Technology

Hydrogen from methane without CO2 emissions

Leave a comment

Production of hydrogen from methane without carbon dioxide emissions is the objective of a project in which KIT is a major partner. At KALLA, the Karlsruhe Liquid-metal Laboratory, researchers are setting up a novel liquid-metal bubble column reactor, in which methane is decomposed into hydrogen and elemental carbon at high temperature. In this project, KIT cooperates with the Institute for Advanced Sustainability Studies (IASS). Today, the initiator of the project and scientific director of IASS, Nobel Prize laureate Professor Carlo Rubbia, met KIT scientists working at KALLA, the Institute for Pulsed Power and Microwave Technology (IHM), and the Institute for Applied Materials – Material Process Technology (IAM-WPT). …read more

Source: FULL ARTICLE at Phys.org

Business, Finance, Occupation & Industry

ARIAD Presents New Preclinical Data Showing Ponatinib Overcomes Resistant Mutations in KIT, an Oncog

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

ARIAD Presents New Preclinical Data Showing Ponatinib Overcomes Resistant Mutations in KIT, an Oncogenic Driver of Gastrointestinal Stromal Tumors

CAMBRIDGE, Mass. & WASHINGTON–(BUSINESS WIRE)– ARIAD Pharmaceuticals, Inc. (NAS: ARIA) today announced the presentation of preclinical data on ponatinib (Iclusig™) at the American Association for Cancer Research (AACR) Annual Meeting 2013, in Washington. The study, “Ponatinib, a pan-BCR-ABL inhibitor, potently inhibits key activating and drug-resistant KIT mutants found in GIST,” shows that ponatinib inhibits activated and mutated forms of KIT, a clinically proven oncogenic driver found in approximately 80 percent of patients with gastrointestinal stromal tumors (GIST).

The structure of Iclusig(TM) (ponatinib) bound to KIT, an oncogenic driver found in approximately 80 percent of patients with gastrointestinal stromal tumors (GIST). (Photo: Business Wire)

According to the American Cancer Society, approximately 4,000 to 5,000 people develop GIST each year in the United States. Approved agents for the treatment of patients with GIST include imatinib for newly-diagnosed patients, sunitinib for patients in whom imatinib has failed, and regorafenib for patients who have failed imatinib and sunitinib. Patients can develop resistance to any of these therapies by acquiring secondary KIT mutations. ARIAD plans to begin a Phase 2 trial of Iclusig in patients with GIST in the second quarter of 2013.

“ARIAD‘s development program for Iclusig focuses on its continued evaluation in patients with CML and exploration of its activity against other clinically validated targets. For the first time we were able to solve the x-ray crystal structure of ponatinib bound to KIT, rationalizing its activity in advance of the Phase 2 trial,” said Timothy P. Clackson, Ph.D., president of research and development and chief scientific officer at ARIAD. “These data provide important support for the use of Iclusig in patients with GIST who have become resistant to prior tyrosine kinase inhibitor therapy.”

The research conducted by ARIAD scientists used a broad panel of cell lines harboring mutant forms of KIT. Ponatinib showed potent activity against activated forms of KIT and against a range of secondary mutations that confer resistance to imatinib and/or sunitinib. These include mutations at the T670I gatekeeper residue and mutations in the activation loop (A-loop), common mutations found in patients who have failed currently available therapies.

About ARIAD

ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company …read more

Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

ARIAD Presents New Preclinical Data Showing Ponatinib is a Potent Inhibitor of RET and FGFR, Two Onc

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

ARIAD Presents New Preclinical Data Showing Ponatinib is a Potent Inhibitor of RET and FGFR, Two Oncogenic Drivers of Non-Small Cell Lung Cancer

CAMBRIDGE, Mass. & WASHINGTON–(BUSINESS WIRE)– ARIAD Pharmaceuticals, Inc. (NAS: ARIA) today announced the presentation of preclinical data on ponatinib (Iclusig™) , at the American Association for Cancer Research (AACR) Annual Meeting 2013, in Washington. In separate studies, ponatinib is shown to potently inhibit RET, a clinically proven oncogenic driver of medullary thyroid cancer (MTC) and non-small cell lung cancer (NSCLC), and FGFR, which is commonly mutated in endometrial, lung and other cancers.

The first preclinical study, “Ponatinib is a highly-potent inhibitor of activated variants of RET found in MTC and NSCLC,” shows that ponatinib inhibits naturally occurring activating mutants of RET found in MTC and NSCLC at clinically achievable plasma concentrations. The potency of ponatinib was found to substantially exceed that of other approved tyrosine kinase inhibitors with RET activity. These results provide strong support for the clinical evaluation of ponatinib in patients with RET-driven cancers.

“The unique design features that allow ponatinib to overcome mutation-based resistance in CML, including the gatekeeper mutation, also apply to its activity against its other tyrosine kinase targets including RET, FGFR and KIT,” stated Timothy P. Clackson, Ph.D., president of research and development and chief scientific officer at ARIAD. “These preclinical data strongly support moving forward with evaluating ponatinib in RET-positive cancers, and we look forward to the start of a Phase 2 investigator-sponsored trial in patients with RET-positive NSCLC in this second quarter of 2013.”

In the second preclinical study, “Ponatinib potently inhibits the activity of mutant variants of FGFR commonly found in endometrial, lung and other cancers,” the ability of ponatinib to inhibit a broad panel of naturally occurring mutant variants of FGFR1, 2, 3, and 4 was evaluated. Ponatinib potently blocked a variety of mutant variants of FGFR, with particularly promising activity against mutant variants of FGFR2 that have been observed in endometrial and squamous cell carcinomas (SCCs) of the lung. Specifically, ponatinib inhibits the eight mutants that make up more than 90 percent of the mutations observed in endometrial cancer patients, and six mutants observed in SCC at clinically achievable plasma concentrations. Ponatinib also shows encouraging activity against FGFR1/3 fusion proteins found in glioblastoma multiforme. These data support clinical evaluation of ponatinib in FGFR-driven cancers, including a Phase 2 investigator-sponsored trial of ponatinib in patients with SCCs that is currently underway and enrolling patients.

About ARIAD
…read more

Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

ARIAD Announces Presentations of Preclinical Data at American Association for Cancer Research Annual

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

ARIAD Announces Presentations of Preclinical Data at American Association for Cancer Research Annual Meeting

CAMBRIDGE, Mass.–(BUSINESS WIRE)– ARIAD Pharmaceuticals, Inc. (NAS: ARIA) today announced its schedule of preclinical data presentations to be made at the American Association for Cancer Research (AACR) Annual Meeting 2013, taking place Saturday, April 6 through Wednesday, April 10, 2013, in Washington.

Listed below are the details of presentations at AACR that describe ARIAD’s product candidates. There will be four presentations of data on ARIAD‘s targeted therapies, Iclusig™ (ponatinib) and AP26113; and one invited talk:

Title: Ponatinib is a highly potent inhibitor of activated variants of RET found in MTC and NSCLC
Date & Time: Monday, April 8, 1:00-5:00 p.m. (Poster)
Abstract: #2084
Location: Hall A-C, Poster Section 38

Title: Ponatinib potently inhibits the activity of mutant variants of FGFR commonly found in endometrial, lung and other cancers
Date & Time: Monday, April 8, 1:00-5:00 p.m. (Poster)
Abstract: #2083
Location: Hall A-C, Poster Section 38

Title: Ponatinib, a pan-BCR-ABL inhibitor, potently inhibits key activating and drug-resistant KIT mutants found in GIST
Date & Time: Tuesday, April 9, 8:00 a.m.-12:00 p.m. (Poster)
Abstract: #3394
Location: Hall A-C, Poster Section 42

Title: Design and development of ponatinib, a pan-BCR-ABL inhibitor for CML
Date & Time: Tuesday, April 9, 9:30-10:00 a.m. (Major symposium)
Presentation: #SY19-04
Location: Salon A-B, East Hall

Title: AP26113 possesses pan-inhibitory activity versus crizotinib-resistant ALK mutants and oncogenic ROS1 fusions
Date & Time: Wednesday, April 10, 8:00 a.m.-12:00 p.m. (Poster)
Abstract: #5655
Location: Hall A-C, Poster Section 42

About ARIAD

ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).

ARIAD
For Investors<br …read more
Source: FULL ARTICLE at DailyFinance

Science & Technology

Bioliq pilot plant: Successful operation of high-pressure entrained flow gasification

Leave a comment

On the way to the production of environment-friendly fuels from biomass residue, the Karlsruher Institut für Technologie, or KIT for short, in cooperation with the technology partner Air Liquide Global E&C Solutions has realized another important milestone: the second process stage of the bioliq pilot plant is ready – today, the complex high-pressure entrained flow gasifier bioliq II was handed over for operation. The four-step process designed at the KIT allows producing valuable and engine-compatible design fuels für diesel and Otto engines. …read more
Source: FULL ARTICLE at Phys.org

Science & Technology

Light from silicon nanocrystal LEDs

Leave a comment

(Phys.org)—Silicon nanocrystals have a size of a few nanometers and possess a high luminous potential. Scientists of KIT and the University of Toronto/Canada have now succeeded in manufacturing silicon-based light-emitting diodes (SiLEDs). They are free of heavy metals and can emit light in various colors. The team of chemists, materials researchers, nanoscientists, and opto-electronic experts presents its development in the Nano Letters journal. …read more
Source: FULL ARTICLE at Phys.org

Science & Technology

Reliable electric power supply for the energy turn-around

Leave a comment

Getting the grid prepared for the increased use of renewable energy sources is the goal of the Helmholtz Energy Alliance “Technologies for the Future Power Grid” coordinated by KIT. Helmholtz researchers are developing solutions for a flexible and reliable grid which manages the fluctuating power supply from renewable energy sources in cooperation with university partners and utilities.
Source: FULL ARTICLE at Phys.org